Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: A systematic review and cost-effectiveness analysis

Health Technology Assessment

Volumn 4, Issue 29, 2000, Pages

  Marks, D ^a   Wonderling, D ^a   Thorogood, M ^a   Lambert, H ^a   Humphries, S E ^a   Neil, H A W ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CHOLESTEROL; COLESTIPOL; COLESTYRAMINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MEVINOLIN; PRAVASTATIN; RESIN; SIMVASTATIN; VITAMIN;

CASE FINDING; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIET THERAPY; DISEASE MODEL; DRUG ABSORPTION; DRUG COST; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; FAMILIAL HYPERCHOLESTEROLEMIA; GASTROINTESTINAL DISEASE; GENE MUTATION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; META ANALYSIS; PATIENT COMPLIANCE; PREVALENCE; PSYCHOLOGICAL ASPECT; PSYCHOSOCIAL CARE; REVIEW; RISK BENEFIT ANALYSIS; SCREENING;

EID: 0033645679     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta4290     Document Type: Review

References (134)

1. Familial hypercholesterolaemia
2. Lipid abnormalities in male and female survivors of myocardial infarction and their first degree relatives
3. Genetic testing for familial hypercholesterolaemia: Practical and ethical issues
4. Risks of ischaemic heart disease in familial hyperlipoproteinaemic states
5. Principles and practice of mass screening for disease
6. Risk of fatal coronary heart disease in familial hypercholesterolaemia
7. Current methods of mutation detection
8. Detection of mutations by cleavage of DNA heteroduplexes with bacterio-phage resolvases
9. SSCP analysis and DNA sequencing for genetic characterization of a multi-allelic disease, familial hypercholesterolaemia
10. Genetic diagnosis with the denaturing gradient gel electrophoresis technique improves diagnostic precision in familial hypercholesterolemia
11. Effect on plasma lipid levels of different classes of mutations in the low-density lipoprotein receptor gene in patients with familial hypercholesterolemia
12. Utilities for high throughput use of the single strand conformational polymorphism method: Screening of 791 patients with familial hypercholesterolemia for mutations in exon 3 of the low density lipoprotein receptor gene
13. Identification of a common low density lipoprotein receptor mutation (R329X) in the south of England: Complete linkage disequilibrium with an allele microsatellite D19S394
14. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
15. Randomised trial of cholesterol lowering in 4444 patients with coronary heart diseases: The Scnadinavian Simvastatin Survival Study (4S)
16. Prevention of cardiovascular events and death with prevastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
17. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
18. Three-year follow-up of the Oxford Cholesterol Study: Assessment of the efficacy and safety of simvastatin in preparation for a large mortality study
19. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
20. Dietary lipids and blood cholesterol: Quantitative meta-analysis of metabolic ward studies
21. Systematic review of dietary intervention trials to lower blood total cholesterol in free-living subjects
22. Modulation of plasma lipids levels and cholesterol kinetics by phytosterol versus phytostanol-esters
23. Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolaemic population
24. Plant sterol-enriched margarines and reduction of plasma total-and LDL-cholesterol concentrations in normocholesterolaemic and mildly hypercholesterolaemic subjects
25. How to read a paper: The basics of evidence based medicine
26. Coronary artery disease in 116 kindred with familial type II hyperproteinemia
27. Heterozygous familial hypercholesterolaemia
28. Ischaemic disease in men and women with familial hypercholesterolaemia and xanthomatosis
29. Coronary disease in familial hypercholesterolemia
30. Mortality in treated heterozygous familial hypercholesterolaemia: Implications for clinical management
31. Neonatal diagnosis of familial hypercholesterolaemia in newborns born to a parent with a molecularly defined heterozygous familial hypercholesterolaemia
32. Neonatal diagnosis of familial hyperlipoproteinemia
33. Diagnosing familial hypercholesterolaemia in childhood by measuring serum cholesterol
34. Long-term follow-up of children with familial hypercholesterolaemia treated with cholestyramine
35. Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia
36. Low dose colestipol in adolescents with familial hypercholesterolaemia
37. Lipid and lipoprotein profiles in children with familial hypercholesterolaemia: Effects of therapy
38. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: A randomized controlled trial
39. Screening for hyperlipidaemia in childhood: Recommendations of the British Hyperlipidaemia Association
40. Familial hypercholesterolaemia
41. Pediatric implications of heterozygous familial hypercholesterolemia: Screening and dietary treatment
42. Identification and treatment of heterozygous familial hypercholesterolemia in children and adolescents
43. National Cholesterol Education Program. Report of the expert panel on blood cholesterol levels in children and adolescents
44. The detection and management of dyslipidaemia in children and adolescents
45. Cost-effectiveness of cholesterol lowering: Results from the Scandinavian Simvastatin Survival Study (4S)
46. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease
47. The West of Scotland coronary prevention study: Economic benefit analysis of primary prevention with pravastatin
48. Strategies for the management of hypercholesterolaemia: A systematic review of the cost-effectiveness literature
49. Cost-effectiveness considerations in the treatment of heterozygous familial hypercholesterolemia with medications
50. Problems of using modelling in the economic evaluation of health care
51. Cholesterol lowering and mortality: The importance of considering initial level of risk
52. Cholesterol and coronary heart disease: Screening and treatment
53. A novel single base deletion in the LDLR gene (211delG): Effect on serum lipid profiles and the influence of other genetic polymorphisms in the ACE, APOE and APOB genes
54. Prevalence of familial hypercholesterolemia among young north Karelian patients with coronary heart disease: A study based on diagnosis by polymerase chain reaction
55. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics
56. Genetic discrimination in life insurance: Empirical evidence from a cross sectional survey of genetic support groups in the United Kingdom
57. Ethical implications of screening asymptomatic individuals
58. Genetic discrimination and health insurance: An urgent need for reform
59. Genetic testing for cancer predisposition: Behavioural science issues
60. Screening for familial hypercholesterolaemia by measurement of apoliproteins in capillary blood
61. Documented need for more effective diagnosis and treatment of familial hypercholesterolemia according to data from 502 heterozygotes in Utah
62. Outcome of case-finding amongst relatives of patients with known heterozygous familial hypercholesterolaemia
63. Incidence of familial hypercholesterolaemia in premature deaths due to coronary heart disease
64. Familial hypercholesterolaemia: Pilot study to identify children at risk
65. Is knowing your cholesterol number harmful?
66. Life style intervention in general practice: Effects on psychological well-being and patient satisfaction
67. Patients' attitudes towards detection of heterozygous familial hypercholesterolemia
68. Causality, responsibility and blame - Core issues in the cultural construction and subtext of prevention
69. Familial hypercholesterolaemia: A pilot study of parents' and children's concerns
70. Cholesterol screening of children at high risk: Behavioural and psychological effects
71. The psychological functioning of children with hypercholesterolaemia and their families: A preliminary investigation
72. Psychological responses to BRCA1 mutation testing: Preliminary findings
73. The influence of psychological distress on use of genetic testing for cancer risk
74. Genetic testing for susceptibility to breast cancer: Findings from women's focus groups
75. Psychological counseling strategies for women at risk of breast cancer
76. Controlled trial of pre-test education approaches to enhance informed decision-making for BRCA1 gene testing
77. The psychological impact of cardiovascular screening and intervention in primary care: A problem of false reassurance?
78. Psychosocial impact of cholesterol screening and management
79. Cholesterol screening and life assurance
80. Discrimination as a consequence of genetic testing
81. Psychosocial function during treatment for familial hypercholesterolemia
82. Psychological aspects of genetic testing: Introduction to the special issue
83. The psychological and social implications of serum cholesterol screening
84. Prevention. How much harm? How much benefit? 3. Physical, psychological and social harm
85. Testing and counseling adults for heritable cancer risk
86. The psychological costs of screening for cancer
87. Psychological responses to genetic testing
88. The potential social impact of predictive genetic testing for susceptibility to common chronic diseases: A review and proposed research agenda
89. The new genetics: Some issues for social scientists
90. Emotional and behavioural responses to genetic testing for susceptibility to cancer
91. Screening in practice: Reducing the psychological costs
92. Labeling of participants in high blood pressure screening programs: Implications for blood cholesterol screenings
93. Psychologic effects of the diagnosis and treatment of hypercholesterolemia: Lessons from case studies
94. Hypertension labelling and well-being: Alternative explanations in cross-sectional data
95. Labelling in hypertension: A review of the behavioural and psychological consequences
96. Labelling of hypertensives: A review of the data
97. Genetic testing and public policy
98. Genetic testing and insurance: Emphasises the irreconcilable dilemma in underwriting
99. Genetic testing: Employability, insurability and health reform
100. Ethics, genetic prediction and heart disease
101. Psychological and ethical considerations in screening for disease
102. Nurse-mediated cholesterol management compared with enhanced primary care in siblings of individuals with premature coronary disease
103. Costs and cost effectiveness of health checks conducted by nurses in primary care: The OXCHECK study
104. Randomised trial of lipid lowering dietary advice in general practice: The effects on serum lipids, lipoproteins, and antioxidants
105. Problems in measurement: Cholesterol
106. Costs and cost effectiveness of cardiovascular screening and intervention: The British family heart study
107. What can be concluded from the OXCHECK study and British family heart studies: Commentary on cost-effectiveness analyses
108. Costs and cost-effectiveness of cardiovascular screening and intervention: Economic evaluation of the British family heart study and comparison with other studies
109. Coronary event and case fatality rates in an English population: Results of the Oxford myocardial infarction incidence study
110. Cost effectiveness of shortening screening interval or extending range of NHS breast screening programme: Computer simulation study
111. A comparison of BRCA1 mutation analysis by direct sequencing, SSCP and DHPLC
112. Optimal temperature selection for mutation detection by denaturing HPLC and comparison to single-stranded conformation polymorphism and heteroduplex analysis
113. Chip-based genotyping by mass spectrometry
114. Genetic localization to chromosome 1p32 of the third locus for familial hypercholesterolemia in a Utah kindred
115. A third major locus for autosomal dominant hypercholesterolaemia maps to 1p34.1-p32
116. Will genetic testing for predisposition for disease result in fatalism? A qualitative study of parents' responses to neonatal screening for familial hypercholesterolaemia
117. Management of hyperlipidaemia: Guidelines of the British Hyperlipidaemia Association